Skip to main content

dividend stocks

4 articles found

Dividend Yield: What It Tells You About Income

When investors talk about living off their portfolio, dividend yield is usually the first number they reach for. It distills a company's cash return to shareholders into a single, comparable percentage — and in a world where the 10-year Treasury yields 4.02% and the federal funds rate sits at 3.64%, that percentage has never been more scrutinised. Dividend yield is deceptively simple: annual dividends per share divided by the share price. Yet behind that fraction lie questions about sustainability, growth, valuation, and opportunity cost that separate informed income investors from yield chasers. A stock yielding 6% may be a bargain or a trap; one yielding 1.5% may be the better long-term compounder. This guide breaks down what dividend yield really measures, how to calculate and interpret it using real market data from companies like Coca-Cola, AbbVie, Johnson & Johnson, and AT&T, and how current interest-rate conditions shape the case for dividend stocks in 2026.

dividend yieldincome investingdividend growth

HD Analysis: Home Depot's $380 Billion Bet on the Pro

Home Depot (NYSE: HD) trades at $382.25 per share with a market capitalization of $380.5 billion, making it the largest home improvement retailer in the world by a wide margin. Despite a persistent housing market slowdown that has depressed existing home sales and kept mortgage rates elevated, the company continues to generate over $166 billion in trailing twelve-month revenue and nearly $16.3 billion in annual free cash flow. The stock sits roughly 10% below its 52-week high of $426.75, reflecting investor caution ahead of the February 24 Q4 earnings report. The housing backdrop remains challenging — higher-for-longer interest rates have frozen the resale market, and tariff uncertainty adds another layer of complexity for a company that imports significant volumes of building materials. Yet Home Depot's strategic pivot toward professional contractors through its $18.25 billion acquisition of SRS Distribution may be the catalyst that redefines its growth trajectory for the next decade. For individual investors, HD presents a classic tension: a best-in-class operator with a dominant market position and consistent cash generation, trading at a premium valuation in a sector facing cyclical headwinds. Understanding whether the Pro strategy can offset housing weakness is the key question for 2026 and beyond.

Home DepotHD stock analysishome improvement stocks

NEE: NextEra Energy Trades Within 3% of Its 52-Week High as

NextEra Energy (NYSE: NEE) has surged 49% from its 52-week low of $61.72 to trade at $92.18, within touching distance of its $94.94 all-time high. The $192 billion utility giant — parent of Florida Power & Light, the nation's largest electric utility, and NextEra Energy Resources, the world's largest generator of wind and solar energy — is riding a powerful convergence of tailwinds that has transformed the utility sector's growth narrative. The company reported full-year 2025 revenue of $27.5 billion and earnings per share of $3.31, delivering consistent profitability even as it pours record capital into renewable energy infrastructure. With a trailing P/E of 27.9x, NEE commands a steep premium over the utility sector average of roughly 17x — a valuation that reflects Wall Street's conviction that this is not a traditional utility but a secular growth story tied to electrification, AI-driven power demand, and the clean energy transition. But the bull case comes with real tension. NextEra's aggressive capital spending — $24.6 billion in 2025 alone — has pushed free cash flow deeply negative, total debt past $95 billion, and the balance sheet to levels that would alarm investors in any other sector. The question for investors isn't whether NextEra is a great company. It's whether the stock, at nearly 28 times earnings and 68 times EBITDA, already prices in perfection.

NextEra EnergyNEE stock analysisutility stocks

JNJ Analysis: At a 52-Week High and Reshaping Its Portfolio

Johnson & Johnson is trading at $246.61, within touching distance of its 52-week high of $246.88 and a staggering 74% above its 52-week low of $141.50. That kind of run from a $594 billion healthcare giant isn't supposed to happen — and yet here we are, watching one of the most defensive names in the market act like a growth stock. The catalyst isn't a single product launch or earnings beat. It's a wholesale reshaping of what JNJ actually is. Today's news that the company is exploring a $20 billion sale of its orthopedics unit, combined with a $1 billion investment in cell therapy manufacturing in Pennsylvania, tells you everything about where management is taking this business: away from commoditized medical devices and toward the high-margin frontier of biologics and cell-based therapies. For investors who bought the Kenvue spinoff dip below $150, the returns have been exceptional. The question now is whether JNJ at 22x earnings still offers value, or whether the portfolio transformation is already priced in.

Johnson & JohnsonJNJstock analysis